Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SEMINAR
July 10, 2006
- Generic Marketing Companies Asked to Cooperate in Follow-up Market Price Surveys
July 10, 2006
- Bayer to Sell Diagnostics Business to Siemens
July 10, 2006
- TOPIC an article
July 10, 2006
- MEDICAL DEVICES/DIAGNOSTICS NEWS IN BRIEF
July 10, 2006
- METI Proposes "Economic Growth Strategy Framework"
July 10, 2006
- NEW PRODUCTS
July 10, 2006
- Council Proposes Cuts of \11.4-14.3 Tril. Over Next 5 Years
July 10, 2006
- SEMINAR
July 10, 2006
- Otsuka's Mozavaptan Recommended for Approval
July 10, 2006
- Asahi Kasei Licenses Fasudil to CoTherix
July 10, 2006
- Proposed Vision Calls For Support of Vaccine Development
July 10, 2006
- SURVEY 2 articles
July 10, 2006
- HPB Sets Up Another Study Group to Promote Clinical Trials
July 10, 2006
- SURVEY 3 articles
July 3, 2006
- Generic Makers Concerned about Extension of Data Protection Period: IGPA Conference
July 3, 2006
- Epadel, Atelec Continue to Drive Mochida's Business
July 3, 2006
- 66th Annual Scientific Sessions of the American Diabetes Association
July 3, 2006
- Blopress Retained Rank as Top-selling Drug in FY2005
July 3, 2006
- Pediatric Clinical Trial of Ketek Temporarily Discontinued in US: sanofi-aventis
July 3, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…